Andere talen Orgenesis Inc.

Aandelen

ORGS

US68619K2042

Vertraagde tijd Nasdaq Andere beurzen 16:23:07 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,5099 ^USD	+1,98%		-1,75%	+1,84%

15/04	Orgenesis Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
10/04	Germfree en Orgenesis Inc. kondigen de aankoop van activa en een strategisch partnerschap aan met als doel een revolutie teweeg te brengen in cel- en gentherapie door middel van gedecentraliseerde productie en wereldwijde toegankelijkheid	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Powell Comments, -2-	16/04
Orgenesis Provides Year End Business Update	15/04
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	15/04
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10/04
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10/04
North American Morning Briefing : Stocks Seen -2-	02/04
North American Morning Briefing : Markets Steady -2-	26/03
North American Morning Briefing : Stock Futures -2-	19/03
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	18/03
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	13/03
Orgenesis Inc. announced that it has received $2.340901 million in funding	05/03
Orgenesis Inc. Announces $2.3 Million Private Placement	04/03
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	03/03
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	29/02
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	31/01
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	31/01
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	24/01
Alimera Sciences Appoints New CFO	02/01
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	14/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Orgenesis Inc.

Aandelen

ORGS

US68619K2042

Andere talen

Filters